FDA Endorses Human-Relevant Nonclinical Models: A Welcome Sh...
by Johannes Stanta, PhD – Global Scientific Director, Sabina Paglialunga, PhD – Senior Scientific Di...
Blog
Ruling the Future: How the ACLA’s LDT Court Victory and Euro...
by Chad Briscoe, Executive Vice President, Global Bioanalytical Services, Celerion Someone whom I’ve...
Blog
Reframing the Definition of Obesity
Sabina Paglialunga, PhD Senior Director, Scientific Affairs Two notable guidance documents addressin...
Blog
GLP-1 Agonist-Induced Delayed Gastric Emptying – A Clinical...
 Your browser does not support the audio element. ⬇ Download MP3 By Sabina Paglialunga, PhD & A...
Blog
How Healthy Volunteer Studies can Accelerate Oncology Drug D...
By Sabina Paglialunga, PhD & Aernout van Haarst, PhD; Senior Directors Scientific Affairs, Celer...
Blog
Key Clinical Pharmacology Studies to Support Biologic Drug R...
By Sabina Paglialunga, PhDÂ & Aernout van Haarst, PhD; Senior Directors Scientific Affairs, Cele...
Blog
12 Questions to Help Guide Renal Impairment PK Study Design
By Sabina Paglialunga, PhDÂ Director Scientific Affairs, Celerion Need to run a renal impairment pha...
Blog
Adaptive Trial Designs
Flexibility of Adaptive Early Phase Study Designs Sabina Paglialunga, PhD Â Director, Scientific Aff...
Blog
A Decade of Innovative Technology to Accelerate Drug Develop...
Celerion continues its Celebration of Translating Science into Medicine for over a decade by highlig...